Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report)’s stock price dropped 2% during mid-day trading on Tuesday . The company traded as low as $6.01 and last traded at $6.22. Approximately 40,935 shares were traded during trading, a decline of 99% from the average daily volume of 2,798,922 shares. The stock had previously closed at $6.35.
Entero Therapeutics Trading Down 9.1%
The stock has a 50 day moving average of $3.56 and a 200-day moving average of $3.16. The company has a market capitalization of $9.19 million, a P/E ratio of -3.43 and a beta of 1.19.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC purchased a new position in Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors own 12.30% of the company’s stock.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
See Also
- Five stocks we like better than Entero Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
